MNG902
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TGF_BETA_SIGNALING+0.607
- TNFA_SIGNALING_VIA_NFKB+0.602
- INFLAMMATORY_RESPONSE+0.443
- HYPOXIA+0.433
- PROTEIN_SECRETION+0.432
- IL6_JAK_STAT3_SIGNALING+0.391
- APOPTOSIS+0.367
- ANDROGEN_RESPONSE+0.354
- PI3K_AKT_MTOR_SIGNALING+0.300
- UNFOLDED_PROTEIN_RESPONSE+0.296
Top 10 suppressed
- E2F_TARGETS-0.374
- OXIDATIVE_PHOSPHORYLATION-0.333
- MYC_TARGETS_V2-0.305
- G2M_CHECKPOINT-0.155
- DNA_REPAIR-0.154
- FATTY_ACID_METABOLISM-0.127
- BILE_ACID_METABOLISM-0.105
- SPERMATOGENESIS-0.087
- PEROXISOME-0.067
- MYC_TARGETS_V1-0.063
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-1369 | Med | Medulloblastoma | 0.860 |
| 2 | TCGA-50-5939-01A-11R-1628-07 | — | cohortA1 | 0.851 |
| 3 | MNG982 | — | — | 0.816 |
| 4 | TCGA-BA-5557-01A-01R-1514-07 | — | — | 0.801 |
| 5 | MNG462 | — | — | 0.799 |
| 6 | TCGA-60-2707-01A-01R-0851-07 | — | cohortSQ1 | 0.798 |
| 7 | MNG901 | — | — | 0.798 |
| 8 | MNG20 | — | — | 0.796 |
| 9 | BS_42Y3YANN | pilocytic astrocytoma | — | 0.792 |
| 10 | BS_WRHDP7WF | EPN | Posterior Fossa EPN | 0.790 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 35 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TGF_BETA_SIGNALING | 0.607 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.602 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.443 | Idelalisib | — uncovered |
| HYPOXIA | 0.433 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.432 | Remibrutinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.391 | Inavolisib | — uncovered |
| APOPTOSIS | 0.367 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.354 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.300 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.296 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.289 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.280 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.271 | Temsirolimus | — uncovered |
| MTORC1_SIGNALING | 0.267 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.258 | Idelalisib | — uncovered |
| COMPLEMENT | 0.256 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.252 | Inavolisib | — uncovered |
| COAGULATION | 0.245 | Binimetinib | — uncovered |
| KRAS_SIGNALING_UP | 0.243 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.233 | Idelalisib | — uncovered |